Evaluation of imaging biomarkers and longitudinal assessment of global and regional cardiac function by cardiac MRI during recovery from COVID-19 infection in a multicenter normalized cohort

Recruiting

• Conditions: Z03.8; Observation for other suspected diseases and conditions

• Registration Number: DRKS00028901
• Lead Sponsor: Klinikum der Universität München, Campus Großhadern

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

All patients (age: >18 years, no gender or ethnicity restrictions) who underwent one or more cardiac MRI examination(s) as a result of detected COVID-19 acquisition (PCR test) in the NAPKON HAP cohort will be included in the analysis.

Exclusion Criteria

- Patients without an existing cardio-MRI examination.
- Lack of evidence of COVID-19 disease.
- Contraindication to MR imaging (metal, renal insufficiency, lack of compliance)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
(i) Evaluation of T1 and T2 mapping with respect to the occurrence of MACE (Major Adverse Cardiac Events)<br>(ii) Differences in gcardiac function according to severity of myocardial injury

Secondary Outcome Measures

Name	Time	Method
Association of anamnestic data with the development of COVID-19-associated myocardial injury.